<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">09-PLCB-RA-1038R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1000720</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Computational Biology/Evolutionary Modeling</subject><subject>Computational Biology/Systems Biology</subject><subject>Infectious Diseases/Antimicrobials and Drug Resistance</subject><subject>Infectious Diseases/HIV Infection and AIDS</subject><subject>Pharmacology/Drug Development</subject><subject>Pharmacology/Drug Resistance</subject><subject>Virology/Antivirals, including Modes of Action and Resistance</subject><subject>Virology/Immunodeficiency Viruses</subject><subject>Virology/New Therapies, including Antivirals and Immunotherapy</subject></subj-group></article-categories><title-group><article-title>Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV</article-title><alt-title alt-title-type="running-head">Drug-Class Specific Impact on HIV</alt-title></title-group><contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>von Kleist</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Menz</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Huisinga</surname><given-names>Wilhelm</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
</contrib-group><aff id="aff1"><label>1</label><addr-line>Hamilton Institute, Computational Physiology Group, National University of Ireland Maynooth, Kildare, Ireland</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Beerenwinkel</surname><given-names>Niko</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">ETH Zurich, Switzerland</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">vkleist@zedat.fu-berlin.de</email></corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: MvK. Performed the experiments: MvK SM. Analyzed the data: MvK SM WH. Wrote the paper: MvK SM WH. Provided guidance and supervision: WH.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>3</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2010</year></pub-date><volume>6</volume><issue>3</issue><elocation-id>e1000720</elocation-id><history>
<date date-type="received"><day>2</day><month>9</month><year>2009</year></date>
<date date-type="accepted"><day>23</day><month>2</month><year>2010</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2010</copyright-year><copyright-holder>von Kleist et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
<p>Predictive markers linking drug efficacy to clinical outcome are a key component in the drug discovery and development process. In HIV infection, two different measures, viral load decay and phenotypic assays, are used to assess drug efficacy <italic>in vivo</italic> and <italic>in vitro</italic>. For the newly introduced class of integrase inhibitors, a huge discrepancy between these two measures of efficacy was observed. Hence, a thorough understanding of the relation between these two measures of drug efficacy is imperative for guiding future drug discovery and development activities in HIV. In this article, we developed a novel viral dynamics model, which allows for a mechanistic integration of the mode of action of all approved drugs and drugs in late clinical trials. Subsequently, we established a link between <italic>in vivo</italic> and <italic>in vitro</italic> measures of drug efficacy, and extract important determinants of drug efficacy <italic>in vivo</italic>. The analysis is based on a new quantity—the reproductive capacity—that represents in mathematical terms the <italic>in vivo</italic> analog of the read-out of a phenotypic assay. Our results suggest a drug-class specific impact of antivirals on the total amount of viral replication. Moreover, we showed that the (drug-)target half life, dominated by immune-system related clearance processes, is a key characteristic that affects both the emergence of resistance as well as the <italic>in vitro</italic>–<italic>in vivo</italic> correlation of efficacy measures in HIV treatment. We found that protease- and maturation inhibitors, due to their target half-life, decrease the total amount of viral replication and the emergence of resistance most efficiently.</p>
</abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>To guide drug discovery and development, measures of drug efficacy that are linked to clinical outcome are of key importance. In HIV treatment, decay of plasma viral load is typically used as an <italic>in vivo</italic> measure of drug efficacy, whereas phenotypic assays are used to assess drug efficacy <italic>in vitro</italic>. The recent development of novel HIV drugs resulted in a huge discrepancy between viral load decay and <italic>in vitro</italic> predictions of drug efficacy. We used a mathematical modelling approach to resolve this discrepancy by introducing a new quantity, the reproductive capacity, that allows a transfer of the <italic>in vitro</italic> drug efficacy measure into the <italic>in vivo</italic> context, enabling a direct comparison. We developed a novel model of viral dynamics that incorporates the mechanism of action of all established and novel antivirals. Based on the model, we analyzed the ability of the viral infection to replicate under different drug treatments, and estimated class-specific times until virological failure. We conclude that the half life of the targeted viral stage is an important class-specific attribute that impacts on the overall success of a drug <italic>in vivo</italic>. Our findings have direct implication for the drug discovery and development process.</p>
</abstract><funding-group><funding-statement>MvK and WH acknowledge funding from National University of Ireland and the DFG Research Center Matheon. SM acknowledges financial support by DFG funding, provided through the Dahlem Research School of Freie Universität Berlin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="13"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Since 1996, human immunodeficiency virus (HIV) infection is treated with a combination therapy, known as highly active anti-retroviral therapy (HAART) <xref ref-type="bibr" rid="pcbi.1000720-Hammer1">[1]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Hirsch1">[2]</xref>, which has substantially improved the clinical management of HIV <xref ref-type="bibr" rid="pcbi.1000720-Richman1">[3]</xref>. Despite the success of HAART, eradication of HIV can currently not be achieved <xref ref-type="bibr" rid="pcbi.1000720-Kulkosky1">[4]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Kulkosky2">[5]</xref>, most likely due to the persistence of virus in very long lived, latently infected cells <xref ref-type="bibr" rid="pcbi.1000720-Finzi1">[6]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Wong1">[7]</xref>. For HIV-infected individuals, life-long therapy is therefore required to prevent progression to the acquired immunodeficiency syndrome (AIDS) and death.</p>
<p>During therapy, plasma viral load (HIV RNA per mL blood plasma) is recommended by the National Institute of Health as a marker of therapy success <xref ref-type="bibr" rid="pcbi.1000720-Current1">[8]</xref>, whereas measurement of the CD4 cell count is the most important clinical marker of disease progression <xref ref-type="bibr" rid="pcbi.1000720-Langford1">[9]</xref>. The <italic>in vivo</italic> potency of novel antivirals is usually assessed by viral load decline in small clinical trials of monotherapy, e.g., <xref ref-type="bibr" rid="pcbi.1000720-Markowitz1">[10]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Ftkenheuer1">[11]</xref>, and later evaluated utilizing the novel agent in combination with an optimized background therapy, e.g., <xref ref-type="bibr" rid="pcbi.1000720-Louie1">[12]</xref>. The <italic>in vitro</italic> potency of antivirals is typically assessed by using phenotypic/single-round infectivity assays <xref ref-type="bibr" rid="pcbi.1000720-Zhang1">[13]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-Hachiya1">[16]</xref>, which measure the number of offspring after one round of virus replication.</p>
<p>Investigation of novel drug targets for the treatment of HIV infection resulted in the development of new drug classes. In 2003 and 2007, the fusion inhibitor (FI) enfuvirtide <xref ref-type="bibr" rid="pcbi.1000720-Dando1">[17]</xref>, the CCR5-antagonist maraviroc <xref ref-type="bibr" rid="pcbi.1000720-Carter1">[18]</xref> and the integrase inhibitor raltegravir <xref ref-type="bibr" rid="pcbi.1000720-Croxtall1">[19]</xref> were approved for the treatment of HIV infection. Many more drugs are in late clinical development <xref ref-type="bibr" rid="pcbi.1000720-Investigational1">[20]</xref>. With the introduction of new drug classes, in particular integrase inhibitors, a huge discrepancy between the efficacy measured <italic>in vitro</italic>, using phenotypic/single-round infectivity assays, and <italic>in vivo</italic>, using viral load decline, was observed <xref ref-type="bibr" rid="pcbi.1000720-Shen1">[14]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref>. Although integrase inhibitors cause a steep initial decline of plasma viral load <xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-DeJesus1">[26]</xref>, the <italic>in vitro</italic> efficacy is amongst the lowest <xref ref-type="bibr" rid="pcbi.1000720-Shen1">[14]</xref>.</p>
<p>Mathematical modelling of viral dynamics has lead to many insights into the pathogenesis and treatment of HIV. It is a valuable tool to interpret the time course of virological markers (e.g. viral load) during HIV treatment <xref ref-type="bibr" rid="pcbi.1000720-Perelson1">[27]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-Nowak1">[31]</xref> and contributes much to our current understanding of the <italic>in vivo</italic> dynamics of HIV. Sedaghat et al. <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref> used a mathematical modelling approach to analyze the rapid decay of plasma viral load after application of integrase inhibitors. They infer that this characteristic viral decay is a result of the inhibited stage within the viral life cycle rather than superior <italic>in vivo</italic> potency.</p>
<p>Consequently, viral load decay may be misleading for assessing the potency of integrase inhibitors (and other novel inhibitors) in comparison to existing drug classes. However, an alternative, more appropriate measure of drug efficacy, which allows to directly compare drugs from different drug classes is still missing.</p>
<p>The objectives of this article are (i) to develop a novel, generic measure of drug potency that facilitates comparison across different drug classes; (ii) to develop a novel mathematical model of the viral replication cycle that incorporates the action of established and novel drugs in a <italic>mechanistic</italic> way; and (iii) to analyze determinants of drug efficacy critical for drug discovery and development. The proposed measure of drug efficacy, termed reproductive capacity, extends the established <italic>in vivo</italic> marker, plasma viral load, by incorporating additional infectious viral stages, and the <italic>in vitro</italic> phenotypic/single-round infectivity assays by taking into account host specific defense mechanisms. This enables us to understand the observed discrepancies between <italic>in vitro</italic> and <italic>in vivo</italic> efficacy for integrase inhibitors, and to elucidate and quantify the role of immune-system related clearance mechanisms in drug action. The results presented herein are of particular value to categorize different molecular targets in the HIV life cycle and are expected to be of significance for guiding future HIV drug discovery and development.</p>
</sec><sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Development of a detailed model of viral life cycle and action of anti-retroviral drugs</title>
<p>We derived a detailed virus-target cell interaction model as depicted in <xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>. The model incorporates the mechanisms of action of all currently approved drugs and some drugs in late clinical development.</p>
<fig id="pcbi-1000720-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.g001</object-id><label>Figure 1</label><caption>
<title>Detailed structural model of the viral life cycle and the mechanisms of action of different anti-retroviral drug classes.</title>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.g001" xlink:type="simple"/></fig>
<p>Target cells are produced by the immune system with some constant rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e001" xlink:type="simple"/></inline-formula>. An infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e002" xlink:type="simple"/></inline-formula> reversibly binds (with effective rate constants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e003" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e004" xlink:type="simple"/></inline-formula>) to a target cell <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e005" xlink:type="simple"/></inline-formula>, forming a complex <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e006" xlink:type="simple"/></inline-formula>. After binding, the virus irreversibly fuses (with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e007" xlink:type="simple"/></inline-formula>) with the target cell and the viral capsid containing the viral genomic RNA is released; this state is denoted by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e008" xlink:type="simple"/></inline-formula>. During reverse transcription (with effective rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e009" xlink:type="simple"/></inline-formula>), genomic viral RNA is irreversibly transformed into a more stable DNA. Viral DNA and viral proteins form the pre-integration complex (PIC), denoted by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e010" xlink:type="simple"/></inline-formula>. In the next step, viral DNA of the PIC is irreversibly integrated into the DNA of the target cell (with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e011" xlink:type="simple"/></inline-formula>), forming the provirus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e012" xlink:type="simple"/></inline-formula>. After integration, the infected cell cannot return to an uninfected stage. From the proviral DNA, viral proteins are amplified and new viruses are released (with effective rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e013" xlink:type="simple"/></inline-formula>). Only a given percentage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e014" xlink:type="simple"/></inline-formula> of the released viruses are correctly assembled immature viruses <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e015" xlink:type="simple"/></inline-formula>, while the remaining percentage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e016" xlink:type="simple"/></inline-formula> are defective virions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e017" xlink:type="simple"/></inline-formula> that might e.g. lack the (<italic>gag-pol</italic>-polyprotein contained) enzymes. During the final step, the viral protease, which is packed into the correctly assembled, immature virions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e018" xlink:type="simple"/></inline-formula>, is responsible for the maturation of the virus. The maturation of HIV virions has been shown to be dependent on the highly ordered cascade of cleavages, governed by differences in the inherent processing rates at each cleavage site <xref ref-type="bibr" rid="pcbi.1000720-Pettit1">[34]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Wiegers1">[35]</xref>. We assume that a fraction <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e019" xlink:type="simple"/></inline-formula> of the released virus matures abnormally, contributing to the pool of defective virions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e020" xlink:type="simple"/></inline-formula>. Successful maturation eventually leads to new infectious virus particles <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e021" xlink:type="simple"/></inline-formula> (with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e022" xlink:type="simple"/></inline-formula> and probability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e023" xlink:type="simple"/></inline-formula>).</p>
<p>Depending on the stage of the life cycle, the host organism has different abilities to clear the virus. It was assumed that infectious, immature and defective virions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e024" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e025" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e026" xlink:type="simple"/></inline-formula>, respectively, are cleared with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e027" xlink:type="simple"/></inline-formula> by the host. The uninfected target cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e028" xlink:type="simple"/></inline-formula>, the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e029" xlink:type="simple"/></inline-formula> stage and the early infected stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e030" xlink:type="simple"/></inline-formula> are assumed to be cleared with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e031" xlink:type="simple"/></inline-formula>, since none of these stages express viral proteins, while the virus-producing late infected cell <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e032" xlink:type="simple"/></inline-formula> is assumed to be cleared with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e033" xlink:type="simple"/></inline-formula>. In addition to cell death, the target cell may fend-off the viral infection by degrading the viral RNA or parts of the PIC, rendering the cell uninfected. RNA is very unstable with a half life ranging from seconds to a maximum of two hours <xref ref-type="bibr" rid="pcbi.1000720-Ross1">[36]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Houseley1">[37]</xref>. Therefore, through degradation or, e.g., by hypermutation through APOBEC3G <xref ref-type="bibr" rid="pcbi.1000720-Mangeat1">[38]</xref>, the viral RNA can be cleared with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e034" xlink:type="simple"/></inline-formula>. The cell might also destroy essential components of the PIC (with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e035" xlink:type="simple"/></inline-formula>) to clear the virus.</p>
<p>The system of ordinary differential equations (ODEs) describing the rate of change of the different viral species and target cells in the detailed model (depicted in <xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>) is given in Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>, Eqs. (S1)–(S8). As typically done in kinetic studies, complex aspects of the viral dynamics are subsumed by ‘lumped’ parameters in the model. For instance, the rate constant of the reverse transcription <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e036" xlink:type="simple"/></inline-formula> contains all the steps necessary to transform the viral RNA into a double stranded DNA. The mechanisms of action of the seven drug classes are based on interfering with the viral life cycle at different stages. We assumed that the effect of a drug on the targeted process is specified by some parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e037" xlink:type="simple"/></inline-formula>, i.e.,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e038" xlink:type="simple"/><label>(1)</label></disp-formula>assuming some underlying averaged drug concentration <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e039" xlink:type="simple"/></inline-formula>, see <xref ref-type="bibr" rid="pcbi.1000720-Rosario1">[39]</xref>, some fifty percent inhibitory concentration <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e040" xlink:type="simple"/></inline-formula>, and some drug specific Hill coefficient <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e041" xlink:type="simple"/></inline-formula>, see <xref ref-type="bibr" rid="pcbi.1000720-Shen1">[14]</xref>. For the purpose of the study, this rough approximation is sufficient, however, it is possible to also use time-varying drug concentration <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e042" xlink:type="simple"/></inline-formula> resulting from some pharmacokinetic model, or to use more mechanistic effects models <xref ref-type="bibr" rid="pcbi.1000720-Jacqmin1">[40]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-vonKleist1">[41]</xref>.</p>
<p>The actions of the different drug classes within the viral life cycle are shown in <xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>. CCR5 antagonists inhibit the association of HIV with the CCR5 receptor in CCR5-tropic virus. They thus affect the association constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e043" xlink:type="simple"/></inline-formula>. Fusion inhibitors (FI) inhibit the process of HIV fusion, affecting <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e044" xlink:type="simple"/></inline-formula>. Activated nucleoside reverse transcriptase inhibitors (NRTI) compete with endogenous deoxynucleoside triphosphates for prolongation of the growing DNA chain, while non-nucleoside reverse transcriptase inhibitors (NNRTI) allosterically inhibit the function of the reverse transcriptase. The effects of both drug classes result in a reduced rate at which the RNA is reversely transcribed into DNA. Integration inhibitors affect the integration of viral DNA into the host genome catalytically <xref ref-type="bibr" rid="pcbi.1000720-Hazuda1">[42]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-Marchand1">[45]</xref>. In the proposed model, this alters the transition rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e045" xlink:type="simple"/></inline-formula> from early infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e046" xlink:type="simple"/></inline-formula> to the late infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e047" xlink:type="simple"/></inline-formula>. Protease inhibitors (PI) bind to the catalytic pocket of the viral protease enzyme, which is responsible for the processing of the viral precursor polyproteins and thus the maturation of viral particles. In the proposed model (<xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>), PIs therefore inhibit maturation by decreasing the maturation constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e048" xlink:type="simple"/></inline-formula>. Maturation inhibitors (MI) bind to the substrate of the viral protease (<italic>Gag</italic>-polyprotein) <xref ref-type="bibr" rid="pcbi.1000720-Salzwedel1">[46]</xref> at a specific site. This binding perturbs the ordered sequence of cleavages that is necessary for proper maturation <xref ref-type="bibr" rid="pcbi.1000720-Krusslich1">[47]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Pettit2">[48]</xref>, resulting in defective virus morphology <xref ref-type="bibr" rid="pcbi.1000720-Li1">[49]</xref>. In the proposed model (<xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>), MIs therefore decrease the probability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e049" xlink:type="simple"/></inline-formula> that immature virus matures normally, increasing the proportion of abnormally matured, defective viruses <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e050" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s2b">
<title>Impact of antiviral drugs on relative abundance of infectious viral stages</title>
<p>We used the detailed virus-target cell interaction model to predict the effect of the different drug classes on the distinct stages of the viral life cycle. In order to enable a direct comparison between the different drug classes, we artificially eliminated the feedback by keeping the uninfected target cell <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e051" xlink:type="simple"/></inline-formula> and the infective virions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e052" xlink:type="simple"/></inline-formula> that ‘enter’ the infection cycle constant (the two leftmost species in <xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>), resulting in ‘downstream’ quasi-steady state numbers <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e053" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e054" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e055" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e056" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e057" xlink:type="simple"/></inline-formula>. For a given drug class and inhibition of the targeted molecular process <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e058" xlink:type="simple"/></inline-formula>, the effect of the drug on the life cycle was quantified by the four ratios<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e059" xlink:type="simple"/><label>(2)</label></disp-formula>as shown in <xref ref-type="fig" rid="pcbi-1000720-g002">Fig. 2</xref>. As expected, the drugs perturb the ratios of viral states that encompass their site of action within the viral life cycle. In the present example, all states that lie downstream of the drugs' target site are affected, while the states that lie upstream are usually not affected. The exception are InIs, which increase the abundance of the preceding stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e060" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000720-g002">Fig. 2A</xref>), while decreasing the number of the subsequent infectious stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e061" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000720-g002">Fig. 2B</xref>). Interestingly, the effect on the ratios is not always a linear function of drug efficacy. PIs and MIs also show a different behavior (<xref ref-type="fig" rid="pcbi-1000720-g002">Fig. 2D</xref>): PIs affect the ratio of infectious-to-defective virions by decreasing the maturation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e062" xlink:type="simple"/></inline-formula>, which lowers the number of infective virions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e063" xlink:type="simple"/></inline-formula>, but also lowers the number of virions that mature abnormally (contributing to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e064" xlink:type="simple"/></inline-formula>). MIs increase the proportion of virus that matures abnormally and decrease the proportion of virus that matures normally, thus decreasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e065" xlink:type="simple"/></inline-formula> and increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e066" xlink:type="simple"/></inline-formula>, without affecting <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e067" xlink:type="simple"/></inline-formula>.</p>
<fig id="pcbi-1000720-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.g002</object-id><label>Figure 2</label><caption>
<title>Mechanistic effects of drug classes on viral infective compartments.</title>
<p>Ratios are affected through treatment with different drug classes. Predictions are based on the detailed model (see <xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>) and mechanistic effect <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e068" xlink:type="simple"/></inline-formula> varying from 0–1. Chosen parameter values: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e069" xlink:type="simple"/></inline-formula></p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.g002" xlink:type="simple"/></fig></sec><sec id="s2c">
<title>Development of a simplified two stage virus dynamics model</title>
<p>The detailed model (<xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>) contains parameters that are difficult to measure and currently not available. We therefore reduced the detailed model based on reasonable quasi-steady state assumptions to obtain a simplified model of virus-target cell interaction dynamics that is parameterizable in terms of established and validated parameter values (see Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>). In particular, we have eliminated the intermediate stages of the cell-virus complex <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e070" xlink:type="simple"/></inline-formula>, the infected cells prior to reverse transcription <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e071" xlink:type="simple"/></inline-formula> and the immature virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e072" xlink:type="simple"/></inline-formula> in the original model (<xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>). As a consequence, we derived a lumped infection rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e073" xlink:type="simple"/></inline-formula>, which describes the infection of a susceptible cell towards the stage, where the viral RNA has been successfully transformed into DNA. We also derived a virus clearance <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e074" xlink:type="simple"/></inline-formula> that is associated with the loss of virus during the intermediate stages before reverse transcription and the release rate constant of infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e075" xlink:type="simple"/></inline-formula>.</p>
<p>The infection rate constant is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e076" xlink:type="simple"/><label>(3)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e077" xlink:type="simple"/></inline-formula> denotes the fusion rate constant, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e078" xlink:type="simple"/></inline-formula> the dissociation constant of the virus-target cell complex, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e079" xlink:type="simple"/></inline-formula> denotes the probability that reverse transcription is successfully completed (see Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>). The lumped virus clearance (loss of virus by, e.g., genome destruction) in the intermediate stages is given by the parameter<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e080" xlink:type="simple"/><label>(4)</label></disp-formula>The number of released, infectious viruses is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e081" xlink:type="simple"/><label>(5)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e082" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e083" xlink:type="simple"/></inline-formula> are the probabilities that the released virus is correctly assembled and matures normally, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e084" xlink:type="simple"/></inline-formula> is the probability that the released virus matures before being cleared by the immune system (see Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>). The lumped model can be parameterized in terms of six unknown parameters (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e085" xlink:type="simple"/></inline-formula>), which equals the number of estimated parameters using standard models <xref ref-type="bibr" rid="pcbi.1000720-Perelson2">[28]</xref>. For the remaining parameters, we have provided values from the literature (see Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>).</p>
<p>In the following, we considered two types of target cells (T-Cells and a longer lived cell population, which we refer to as macrophages) and finally incorporated the viral mutation process (resulting from erroneous reverse transcription) into the overall model. Whether the longer lived cell population consists solely of macrophages <italic>in vivo</italic> remains unknown. There is, however, some evidence that the kinetic characteristics of the longer lived cell population are similar to those of the macrophage population <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref>. The proposed simplified two-stage virus dynamics model is shown in <xref ref-type="fig" rid="pcbi-1000720-g003">Fig. 3</xref>. It comprises T-cells, macrophages, free non-infectious virus (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e086" xlink:type="simple"/></inline-formula>, respectively), free infectious virus of mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e087" xlink:type="simple"/></inline-formula>, and four types of infected cells belonging to mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e088" xlink:type="simple"/></inline-formula>: infected T-cells and macrophages <italic>prior</italic> to proviral genomic integration (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e089" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e090" xlink:type="simple"/></inline-formula>, respectively) and infected T-cells and macrophages <italic>after</italic> proviral genomic integration (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e091" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e092" xlink:type="simple"/></inline-formula>, respectively). The rates of change of the different species in the reduced two-stage HIV model are given by the following system of ODEs:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e093" xlink:type="simple"/><label>(6)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e094" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e095" xlink:type="simple"/></inline-formula> are the birth rates of uninfected T-cells and macrophages, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e096" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e097" xlink:type="simple"/></inline-formula> are their death rate constants. The parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e098" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e099" xlink:type="simple"/></inline-formula> are the integration rate constants of mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e100" xlink:type="simple"/></inline-formula>. The parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e101" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e102" xlink:type="simple"/></inline-formula> are the death rate constants of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e103" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e104" xlink:type="simple"/></inline-formula> cells. The parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e105" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e106" xlink:type="simple"/></inline-formula> refer to the intracellular degradation of essential components of the pre-integration complex, e.g., by the host cell proteasome within early infected T-cells and macrophages respectively. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e107" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e108" xlink:type="simple"/></inline-formula> denote the total number of released infectious and non-infectious virus from late infected T-cells and macrophages of mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e109" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e110" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e111" xlink:type="simple"/></inline-formula> are the rates of release of infective virus (see Eq (5)). The parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e112" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e113" xlink:type="simple"/></inline-formula> denote the clearance of mutant virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e114" xlink:type="simple"/></inline-formula> through unsuccessful infection of T-cells and macrophages respectively (see Eq. (4)) and the parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e115" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e116" xlink:type="simple"/></inline-formula> denote the successful infection rate constants of mutant virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e117" xlink:type="simple"/></inline-formula> for T-cells and macrophages respectively. The parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e118" xlink:type="simple"/></inline-formula> denotes the probability to mutate from strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e119" xlink:type="simple"/></inline-formula> to strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e120" xlink:type="simple"/></inline-formula> (to be defined below).</p>
<fig id="pcbi-1000720-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.g003</object-id><label>Figure 3</label><caption>
<title>Simplified two stage virus dynamics model.</title>
<p>Species (red cycles), reactions (black arrows), drugs and their interference in the life cycle of HIV (blue dashed box). Target cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e121" xlink:type="simple"/></inline-formula>) can become successfully infected by infective virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e122" xlink:type="simple"/></inline-formula> with lumped infection rate constants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e123" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e124" xlink:type="simple"/></inline-formula>, respectively, creating early infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e125" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e126" xlink:type="simple"/></inline-formula>. Infection can also be unsuccessful after the irreversible step of fusion (rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e127" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e128" xlink:type="simple"/></inline-formula>), eliminating the virus and rendering the cell uninfected. Early infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e129" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e130" xlink:type="simple"/></inline-formula> can destroy essential viral proteins or DNA prior to integration with rate constants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e131" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e132" xlink:type="simple"/></inline-formula> returning the cell to an uninfected stage. The genomic viral DNA can become integrated with rate constants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e133" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e134" xlink:type="simple"/></inline-formula> creating late infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e135" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e136" xlink:type="simple"/></inline-formula>, which can release new infectious- and non infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e137" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e138" xlink:type="simple"/></inline-formula> with rate constants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e139" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e140" xlink:type="simple"/></inline-formula>, respectively. Phenotypic mutation occurs at the stage of viral genomic integration <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e141" xlink:type="simple"/></inline-formula> (see section ‘Development of a simplified two stage virus dynamics model’). All cellular compartments <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e142" xlink:type="simple"/></inline-formula> can get destroyed by the immune system with respective rate constants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e143" xlink:type="simple"/></inline-formula> and the free virus gets cleared with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e144" xlink:type="simple"/></inline-formula>.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.g003" xlink:type="simple"/></fig>
<p>The model enabled us to mechanistically incorporate the action of all drugs that are approved or in late clinical trial. The impact of a compound on a corresponding (lumped) parameter in the model is specified by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e145" xlink:type="simple"/></inline-formula>:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e146" xlink:type="simple"/><label>(7)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e147" xlink:type="simple"/><label>(8)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e148" xlink:type="simple"/><label>(9)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e149" xlink:type="simple"/><label>(10)</label></disp-formula>The same quantities are defined for macrophages by replacing the subscript <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e150" xlink:type="simple"/></inline-formula> by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e151" xlink:type="simple"/></inline-formula>; see Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref> for details. The overall viral dynamics model comprises a complete mutagenic graph. In HIV infection, genomic mutation occurs during the reverse transcription process <xref ref-type="bibr" rid="pcbi.1000720-Mansky1">[50]</xref>. The reverse transcriptase of HIV lacks a proof reading mechanism in contrast to host polymerase enzymatic reactions. However, viral proteins from newly mutated viral genomes are only produced after integration of the viral genome into the host cell DNA. The proteins required for the stable integration of the newly mutated viral genome originate from the founder virus. Therefore, phenotypically, drug resistance of new mutants will only be observed after integration, i.e., in the infectious stages <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e152" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e153" xlink:type="simple"/></inline-formula>. In total, the model includes <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e154" xlink:type="simple"/></inline-formula> different viral strains <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e155" xlink:type="simple"/></inline-formula> that contain point mutations in any pattern of the modelled <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e156" xlink:type="simple"/></inline-formula> possible mutations. For two distinct mutations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e157" xlink:type="simple"/></inline-formula>, the mutagenic graph is shown in <xref ref-type="fig" rid="pcbi-1000720-g004">Fig. 4A</xref>. Each mutant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e158" xlink:type="simple"/></inline-formula> can mutate into every other mutant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e159" xlink:type="simple"/></inline-formula> in one step. The probability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e160" xlink:type="simple"/></inline-formula> to mutate from a strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e161" xlink:type="simple"/></inline-formula> into another strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e162" xlink:type="simple"/></inline-formula> can be directly derived from the mutagenic pathways in <xref ref-type="fig" rid="pcbi-1000720-g004">Fig. 4A</xref>, i.e.,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e163" xlink:type="simple"/><label>(11)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e164" xlink:type="simple"/></inline-formula> denotes the mutation probability per base and reverse transcription process (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e165" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000720-Mansky1">[50]</xref>), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e166" xlink:type="simple"/></inline-formula> denotes the hamming distance between strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e167" xlink:type="simple"/></inline-formula> and strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e168" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e169" xlink:type="simple"/></inline-formula> is the total number of different positions that are considered in our model. The phenotype of each mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e170" xlink:type="simple"/></inline-formula> is modelled by introducing a selective disadvantage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e171" xlink:type="simple"/></inline-formula>, which denotes the loss of functionality (e.g., in the activity of some viral enzyme that is affected by the mutation) relative to the wild type, and a strain specific inhibitory activity (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e172" xlink:type="simple"/></inline-formula>) of treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e173" xlink:type="simple"/></inline-formula> against the mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e174" xlink:type="simple"/></inline-formula>. For example, the strain specific infection rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e175" xlink:type="simple"/></inline-formula> under a certain treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e176" xlink:type="simple"/></inline-formula> is given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e177" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e178" xlink:type="simple"/></inline-formula> denotes the infection rate constant of the wild type <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e179" xlink:type="simple"/></inline-formula> in the absence of drug <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e180" xlink:type="simple"/></inline-formula> (given in <xref ref-type="table" rid="pcbi-1000720-t001">Table 1</xref>). Since some viral strains are present only in very low copy numbers, we used a hybrid stochastic deterministic approach <xref ref-type="bibr" rid="pcbi.1000720-Alfonsi1">[51]</xref> to model the overall virus dynamics model (see <xref ref-type="sec" rid="s4"><italic>Materials and Methods</italic></xref> section for details).</p>
<fig id="pcbi-1000720-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.g004</object-id><label>Figure 4</label><caption>
<title>Fitness and possible mutational pathways.</title>
<p>A: General transition pathways between wild type (00) and a fully drug resistant strain (11) that involves two partly-resistant intermediates (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e181" xlink:type="simple"/></inline-formula>). B: Fitness in the presence of a drug. C: Fitness in the absence of drugs. Dashed line: critical fitness that allows the strain to survive, i.e, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e182" xlink:type="simple"/></inline-formula>.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.g004" xlink:type="simple"/></fig><table-wrap id="pcbi-1000720-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.t001</object-id><label>Table 1</label><caption>
<title>Model parameters generally used in simulations.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000720-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.t001" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Parameter</td>
<td align="left" colspan="1" rowspan="1">Value</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
<td align="left" colspan="1" rowspan="1">Parameter</td>
<td align="left" colspan="1" rowspan="1">Value</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e183" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e184" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Wei1">[57]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e185" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e186" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e187" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e188" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e189" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e190" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e191" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e192" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">1000</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e193" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e194" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.02</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e195" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.0069</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e196" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Markowitz3">[73]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e197" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.09</td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e198" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e199" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">23</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Markowitz3">[73]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e200" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.67</td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e201" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e202" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.33</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Pierson1">[74]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Zhou1">[75]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e203" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e204" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Mansky1">[50]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e205" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.35</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Zhou1">[75]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e206" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.07</td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e207" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e208" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.35</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Zhou1">[75]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Koelsch1">[76]</xref></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e209" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.0035</td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e210" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e211" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000720-Pettit1">[34]</xref></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>All parameters in units [1/day], except <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e212" xlink:type="simple"/></inline-formula> (unit less) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e213" xlink:type="simple"/></inline-formula> in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e214" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e215" xlink:type="simple"/></inline-formula> parameters chosen to reproduce clinical data. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e216" xlink:type="simple"/></inline-formula> chosen according to the assumption that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e217" xlink:type="simple"/></inline-formula> and utilizing parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e218" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e219" xlink:type="simple"/></inline-formula> to determine <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e220" xlink:type="simple"/></inline-formula>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2d">
<title>Reproductive capacity for predicting drug–specific impact on viral replication</title>
<p>The production of infectious offspring is crucial for the survival of a viral population. The phenotypic single-round infectivity assay measures the amount of infectious offspring after one round of replication. For a given drug, the assay quantifies the drug's efficacy by measuring the reduction in viral offspring relative to the drug-free situation. We defined a new quantity—termed the reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e221" xlink:type="simple"/></inline-formula>—, which transfers the principle of the phenotypic single-round infectivity assay into a mathematical term. Its definition involves the quasi-species distribution and the basic reproductive numbers of all pathogenic sub-stages. The reproductive capacity characterizes the fitness of a given state of the infection from the perspective of a potential treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e222" xlink:type="simple"/></inline-formula> by quantifying the expected total number of offspring under the treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e223" xlink:type="simple"/></inline-formula>.</p>
<p>The basic reproductive number <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e224" xlink:type="simple"/></inline-formula> is a well characterized quantity in epidemiology that denotes the expected number of secondary infections caused by a single infected cell/virus <xref ref-type="bibr" rid="pcbi.1000720-Heesterbeek1">[52]</xref>. If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e225" xlink:type="simple"/></inline-formula> then the infection will spread, while for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e226" xlink:type="simple"/></inline-formula> the infection will die out. The strain associated reproductive number <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e227" xlink:type="simple"/></inline-formula> characterizes the fitness of a viral strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e228" xlink:type="simple"/></inline-formula> in a pharmacologically modified environment, specified by a drug treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e229" xlink:type="simple"/></inline-formula>. We used the ‘survival function’ approach <xref ref-type="bibr" rid="pcbi.1000720-Heffernan1">[53]</xref> to calculate the reproductive numbers for mutant strains <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e230" xlink:type="simple"/></inline-formula> under treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e231" xlink:type="simple"/></inline-formula>. In our context, the survival function is of particular value, since it captures the possible event of mutation for all infective classes.</p>
<p>Based on the two-stage virus dynamics model, the basic reproductive number <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e232" xlink:type="simple"/></inline-formula> of a single virus of strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e233" xlink:type="simple"/></inline-formula> under treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e234" xlink:type="simple"/></inline-formula> is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e235" xlink:type="simple"/><label>(12)</label></disp-formula>with constants<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e236" xlink:type="simple"/><label>(13)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e237" xlink:type="simple"/><label>(14)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e238" xlink:type="simple"/><label>(15)</label></disp-formula>Since infected cells are also pathogens, which can lead to a rebound of the disease even in the absence of any virus, we also determined their basic reproductive numbers under a given treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e239" xlink:type="simple"/></inline-formula>. The basic reproductive numbers <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e240" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e241" xlink:type="simple"/></inline-formula> of the infectious stages <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e242" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e243" xlink:type="simple"/></inline-formula>, associated with the viral strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e244" xlink:type="simple"/></inline-formula>, are given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e245" xlink:type="simple"/><label>(16)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e246" xlink:type="simple"/><label>(17)</label></disp-formula>Finally, the reproductive numbers <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e247" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e248" xlink:type="simple"/></inline-formula> of the infectious stages <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e249" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e250" xlink:type="simple"/></inline-formula>, associated with the viral strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e251" xlink:type="simple"/></inline-formula>, are given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e252" xlink:type="simple"/><label>(18)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e253" xlink:type="simple"/><label>(19)</label></disp-formula>We defined the reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e254" xlink:type="simple"/></inline-formula> of the entire quasi-species ensemble under treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e255" xlink:type="simple"/></inline-formula> as the weighted sum of the basic reproductive numbers of all pathogenic stages of mutant strain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e256" xlink:type="simple"/></inline-formula>, i.e., free virus, infected T-cells and infected macrophages, where the weights are the abundance of the corresponding pathogenic stage:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e257" xlink:type="simple"/><label>(20)</label></disp-formula>The reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e258" xlink:type="simple"/></inline-formula> can be interpreted as the expected total number of infectious offspring that the infection produces in one round of replication under a certain treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e259" xlink:type="simple"/></inline-formula>, given the current state of the infection.</p>
<sec id="s2d1">
<title>Relation to viral load and phenotypic/single-round infectivity assay</title>
<p>The viral load considers the total concentration of free virus, consisting of non-infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e260" xlink:type="simple"/></inline-formula> and infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e261" xlink:type="simple"/></inline-formula>, belonging to all mutant strains <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e262" xlink:type="simple"/></inline-formula>. In contrast to the reproductive capacity, viral load does not assess the ability of distinct viral strains <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e263" xlink:type="simple"/></inline-formula> to replicate (in terms of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e264" xlink:type="simple"/></inline-formula>). In mathematical terms, the viral load is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e265" xlink:type="simple"/><label>(21)</label></disp-formula>The <italic>in vitro</italic> reproductive capacity, corresponding to the read-out of the phenotypic assay <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e266" xlink:type="simple"/></inline-formula> (under treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e267" xlink:type="simple"/></inline-formula>) is conceptionally similar to Eq. (20). However, in comparison to the above defined <italic>in vivo</italic> measure, the <italic>in vitro</italic> measure would not take into account: (i) the clearance of any infective stage by the immune system (relating to the parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e268" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e269" xlink:type="simple"/></inline-formula>), and (ii) the abundance of the different infected cell types (e.g., T-cells and macrophages). The assay measures one round of replication, denoted by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e270" xlink:type="simple"/></inline-formula>, starting from a late stage infected cell <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e271" xlink:type="simple"/></inline-formula>. Mathematically expressed, the primary output is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e272" xlink:type="simple"/><label>(22)</label></disp-formula></p>
</sec></sec><sec id="s2e">
<title>Drug-class specific decay of viral load and reproductive capacity</title>
<p>Application of drugs/drug classes changes the total size and the composition of the viral population. The impact of this change is typically evaluated in terms of the decay of the viral load over time. We used the reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e273" xlink:type="simple"/></inline-formula> to also evaluate viral replication under various hypothetical treatments <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e274" xlink:type="simple"/></inline-formula>. In <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5</xref>, we predicted the impact of the different drug classes on the decay of the plasma viral load and the reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e275" xlink:type="simple"/></inline-formula>, i.e., the fitness of the whole virus population, evaluated in the absence of drugs. As typically done, we assumed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e276" xlink:type="simple"/></inline-formula> drug efficacy <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e277" xlink:type="simple"/></inline-formula>.</p>
<fig id="pcbi-1000720-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.g005</object-id><label>Figure 5</label><caption>
<title>Decay of viral load and reproductive capacity after treatment initiation.</title>
<p>A: Plasma virus load decay after treatment initiation. Integrase inhibitors (InI) produce a faster decay of virus load than all other compound classes. Red solid-, black dotted-, green dash-dotted- and blue dashed lines indicate simulation results with different inhibitor classes and parameters from <xref ref-type="table" rid="pcbi-1000720-t001">Table 1</xref>. Black diamonds indicate median viral load data from <xref ref-type="bibr" rid="pcbi.1000720-Perelson1">[27]</xref> (PI monotherapy), numerically available in <xref ref-type="bibr" rid="pcbi.1000720-Rong2">[70]</xref>. Black squares and black bullets indicate median viral load data from <xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref> (NRTI + background therapy and InI+background therapy, respectively). The horizontal dashed black line indicates the limit of detection of current assays (50 copies of HIV RNA per mL). Inset: Protease- and maturation inhibitors (PI and MI) change the ratio of infectious to total virus (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e278" xlink:type="simple"/></inline-formula>). B: The evolution of the reproductive capacity (evaluated at the drug free state <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e279" xlink:type="simple"/></inline-formula>) after treatment with different drug classes. Model parameters are as indicated in <xref ref-type="table" rid="pcbi-1000720-t001">Table 1</xref>. The initial infection was assumed to consist of wild type only. Drug efficacy <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e280" xlink:type="simple"/></inline-formula> was assumed to be 100%. Total body virus has been converted to plasma viral load by assuming that the virus distributes into the plasma (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e281" xlink:type="simple"/></inline-formula> liters, which surrounds 2% of infected cells) and the interstitial space (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e282" xlink:type="simple"/></inline-formula> liters <xref ref-type="bibr" rid="pcbi.1000720-Kawai1">[71]</xref>, which surrounds 98% of infected cells). The volume of distribution with reference to the plasma concentration has been calculated using the well-known formula vol. distr <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e283" xlink:type="simple"/></inline-formula>, see e.g. <xref ref-type="bibr" rid="pcbi.1000720-vonKleist2">[72]</xref>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e284" xlink:type="simple"/></inline-formula>. Finally, we assume that on average each virus contains 2 viral RNAs (which are measured [viral RNA/mL] plasma).</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.g005" xlink:type="simple"/></fig>
<p>In terms of the plasma viral load decay (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>), we observe a faster initial decay for InIs in comparison to all other compound classes, in agreement with clinical data <xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref> and theoretical analysis <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref>. The onset of viral load decay is delayed for all other compound classes as observed clinically <xref ref-type="bibr" rid="pcbi.1000720-Louie1">[12]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Perelson1">[27]</xref>, see also <xref ref-type="supplementary-material" rid="pcbi.1000720.s002">Figure S1</xref>. In agreement with clinical data <xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref>, in the case of InI treatment, the second phase of viral decay starts earlier after treatment initiation and exhibits <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e285" xlink:type="simple"/></inline-formula> less viremia in comparison to other drug classes, but shows the same decay. Notably, the change of the ratio of infective virus-to-total virus (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5</xref>, inset) upon PI or MI administration is not reflected by the total viral decay in the blood plasma.</p>
<p>Most noticeable, the reproductive capacity (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>) discriminates between RTIs, FIs and CCR5-antagonists vs. InI vs. PIs and MIs. It can be seen, that protease and maturation inhibitors reduce <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e286" xlink:type="simple"/></inline-formula> most efficiently initially and shift it to an overall lower level. Integrase inhibitors cause a slightly faster initial decay in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e287" xlink:type="simple"/></inline-formula>, in comparison to RTIs, FIs and CCR5-antagonists, which consistent with the rapid decay in viral load (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>). However, in contrast to viral load decay, the initial fast decay of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e288" xlink:type="simple"/></inline-formula> levels off and the second phase decay is flatter for InIs in comparison to RTIs, FIs, CCR5-antagonists, PIs and MIs. The effect of NRTIs, NNRTIs, CCR5 inhibitors and FIs on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e289" xlink:type="simple"/></inline-formula> is comparable (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>). Remarkably, these inhibitors induce an initial increase in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e290" xlink:type="simple"/></inline-formula> (see next section for details), followed by a slow first phase decay, followed by a second phase decay that is parallel to the decay of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e291" xlink:type="simple"/></inline-formula> in the case of PI- and MI-treatment, sustaining overall higher levels of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e292" xlink:type="simple"/></inline-formula> in comparison to PIs and MIs. In the next section, we further elucidate the reasons for these class-specific differences.</p>
</sec><sec id="s2f">
<title>Immune-system related clearance is critical determinant of drug-class specific decay</title>
<p>In view of the analysis performed in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e293" xlink:type="simple"/></inline-formula> is directly correlated to the overall abundance of viral infectives (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e294" xlink:type="simple"/></inline-formula>).</p>
<p>PIs and MIs primarily act on infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e295" xlink:type="simple"/></inline-formula> (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5</xref>, inset), by reducing the proportionality factor (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e296" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e297" xlink:type="simple"/></inline-formula>) that determines the abundance of infectious virus in the first- and second phase decay (see Eq. (10)). The infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e298" xlink:type="simple"/></inline-formula> is rapidly cleared by the immune system <xref ref-type="bibr" rid="pcbi.1000720-Ramratnam1">[54]</xref>. Therefore, application of highly efficient PIs and MIs leads to a rapid reduction of infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e299" xlink:type="simple"/></inline-formula>, as illustrated in <xref ref-type="fig" rid="pcbi-1000720-g006">Fig. 6D</xref> and <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5</xref> (inset). This reduction is also reflected by the initial drop of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e300" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>. In the case of PI and MI treatment, infected T-cells are quickly becoming the most abundant infectious compartment (<xref ref-type="fig" rid="pcbi-1000720-g006">Fig. 6D</xref>) and subsequently dominate the decay characteristics of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e301" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>. In the final phase, late infected macrophages (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e302" xlink:type="simple"/></inline-formula>) are becoming the most abundant compartment and thus dominate the decay of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e303" xlink:type="simple"/></inline-formula> in the final phase.</p>
<fig id="pcbi-1000720-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.g006</object-id><label>Figure 6</label><caption>
<title>Decay of infective compartments after initiation of drug treatment.</title>
<p>A: Decay of infective compartments after treatment with FI and CCR5-antagonists. B: Decay of infective compartments after treatment with NRTIs and NNRTIs. C: Decay of infective compartments after treatment with InIs. D: Decay of infective compartments after treatment with PIs.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.g006" xlink:type="simple"/></fig>
<p>Integrase inhibitors prevent the integration of the viral genome and thus prevent the transition of early infected cells (pre-integration, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e304" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e305" xlink:type="simple"/></inline-formula>) to late infected cells (post-integration, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e306" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e307" xlink:type="simple"/></inline-formula>), see <xref ref-type="fig" rid="pcbi-1000720-g003">Fig. 3</xref>. By inhibiting the transition from early to late infectious cells, integrase inhibitors increase the decay of late infected <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e308" xlink:type="simple"/></inline-formula>-cells (see <xref ref-type="fig" rid="pcbi-1000720-g006">Fig. 6C</xref>). In the case of InI treatment, infectious virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e309" xlink:type="simple"/></inline-formula> is initially proportional to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e310" xlink:type="simple"/></inline-formula>, explaining the observed more rapid first-phase decline in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e311" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>. However, blocking the transition from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e312" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e313" xlink:type="simple"/></inline-formula> can also slow the decay of the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e314" xlink:type="simple"/></inline-formula>-compartment, which might become more abundant than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e315" xlink:type="simple"/></inline-formula> after the initial decay. In the final phase both <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e316" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e317" xlink:type="simple"/></inline-formula> become proportional to- and remain more abundant than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e318" xlink:type="simple"/></inline-formula>, which explains the overall higher levels of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e319" xlink:type="simple"/></inline-formula> in the final phase (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>).</p>
<p>The effects of NRTIs, NNRTIs, CCR5 inhibitors and FIs on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e320" xlink:type="simple"/></inline-formula> are comparable (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>), as they primarily act on pre-integrative early infected cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e321" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e322" xlink:type="simple"/></inline-formula>). The difference between entry inhibitors and reverse transcriptase inhibitors is marginal, because the clearance of virus by infection is negligible compared to the clearance by the immune system (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e323" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e324" xlink:type="simple"/></inline-formula>). A positive result of entry inhibitors (FI/CCR5) and RTIs (NRTIs/NNRTIs) is an increased number of uninfected cells, which also results in an initial increase in the reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e325" xlink:type="simple"/></inline-formula> (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>). During treatment with NRTIs, NNRTIs, CCR5 inhibitors and FIs, infective virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e326" xlink:type="simple"/></inline-formula> is the most abundant compartment. The decay in the first phase is proportional to the decay of the late infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e327" xlink:type="simple"/></inline-formula>. Once the abundance of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e328" xlink:type="simple"/></inline-formula> falls below <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e329" xlink:type="simple"/></inline-formula>, the decay of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e330" xlink:type="simple"/></inline-formula> and thus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e331" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref> is proportional to the decay of late infected macrophages <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e332" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s2g">
<title>The pattern of virological removal influences the time to virological rebound after treatment application</title>
<p>In the following, we predict how the distinct viral dynamics after drug application affect drug efficacy <italic>in vivo</italic>. The long-term <italic>in vivo</italic> efficacy of an antiviral drug depends on many different factors, including the ability of the virus to adapt to the pharmacological challenge by developing resistance mutations. The ability to develop drug resistance is strongly dependent on the induced pattern of resistance mutations against a particular drug, but also on the velocity at which replication competent compartments (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e333" xlink:type="simple"/></inline-formula>) are removed from the body. Since anti-retroviral drug classes target different stages in the viral life cycle, they are likely to induce different patterns by which viral compartments are removed from the body (see <xref ref-type="fig" rid="pcbi-1000720-g006">Fig. 6</xref>) and might therefore exhibit different long-term <italic>in vivo</italic> efficacies.</p>
<p>To illustrate the sole impact of virological removal (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e334" xlink:type="simple"/></inline-formula>) on resistance development and therefore on drug efficacy, we have intentionally chosen a simplistic, unified mutational landscape and considered the time to viral rebound as a long-term measure of efficacy. We denoted virological rebound, if the viral load reaches 90% of the pre-treatment viral load. We assumed that the drugs inhibited their targeted (lumped) parameter (see Eqs. (7)–(10)) by 90% in the wild type (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e335" xlink:type="simple"/></inline-formula>), by 45% in a one-mutation strain (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e336" xlink:type="simple"/></inline-formula>) and are entirely inefficient in the double-mutant (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e337" xlink:type="simple"/></inline-formula>). Drug-specific and more realistic mutational landscapes are possible, but in view of the current analysis (elucidating the impact of class-specific virological removal), they would blur the results.</p>
<p>In <xref ref-type="table" rid="pcbi-1000720-t002">Table 2</xref>, the time to virological rebound for the different drug classes based on the above simplistic mutation model is reported. The virus generally rebounds to 90% of pre-treatment levels after 1–2 month of monotherapy, which is in the same order of magnitude as clinically observed rebound times <xref ref-type="bibr" rid="pcbi.1000720-Nijhuis1">[55]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-Wei1">[57]</xref>. Although inhibition <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e338" xlink:type="simple"/></inline-formula> was assumed to be identical across all drug classes, the times to virological rebound differed. In particular, when resistance confers a marked loss in fitness (i.e. selective disadvantage = 30%), PIs show the longest time to virologically rebound, and the InIs the shortest.</p>
<table-wrap id="pcbi-1000720-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000720.t002</object-id><label>Table 2</label><caption>
<title>Virological rebound times resulting from distinct virological removal.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000720-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.t002" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Drug/Selec. Disadvantage</td>
<td align="left" colspan="1" rowspan="1">30%</td>
<td align="left" colspan="1" rowspan="1">25%</td>
<td align="left" colspan="1" rowspan="1">20%</td>
<td align="left" colspan="1" rowspan="1">15%</td>
<td align="left" colspan="1" rowspan="1">10%</td>
<td align="left" colspan="1" rowspan="1">5%</td>
<td align="left" colspan="1" rowspan="1">1%</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">InI</td>
<td align="left" colspan="1" rowspan="1">48.13</td>
<td align="left" colspan="1" rowspan="1">44.44</td>
<td align="left" colspan="1" rowspan="1">41.33</td>
<td align="left" colspan="1" rowspan="1">38.70</td>
<td align="left" colspan="1" rowspan="1">36.43</td>
<td align="left" colspan="1" rowspan="1">34.65</td>
<td align="left" colspan="1" rowspan="1">33.25</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FI/CCR5-antag.</td>
<td align="left" colspan="1" rowspan="1">53.71</td>
<td align="left" colspan="1" rowspan="1">47.81</td>
<td align="left" colspan="1" rowspan="1">43.09</td>
<td align="left" colspan="1" rowspan="1">39.57</td>
<td align="left" colspan="1" rowspan="1">36.47</td>
<td align="left" colspan="1" rowspan="1">33.77</td>
<td align="left" colspan="1" rowspan="1">32.06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NRTI/NNRTI</td>
<td align="left" colspan="1" rowspan="1">55.51</td>
<td align="left" colspan="1" rowspan="1">48.76</td>
<td align="left" colspan="1" rowspan="1">43.86</td>
<td align="left" colspan="1" rowspan="1">39.99</td>
<td align="left" colspan="1" rowspan="1">36.61</td>
<td align="left" colspan="1" rowspan="1">33.94</td>
<td align="left" colspan="1" rowspan="1">32.11</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PI/MI</td>
<td align="left" colspan="1" rowspan="1">55.28</td>
<td align="left" colspan="1" rowspan="1">49.03</td>
<td align="left" colspan="1" rowspan="1">43.74</td>
<td align="left" colspan="1" rowspan="1">39.84</td>
<td align="left" colspan="1" rowspan="1">36.66</td>
<td align="left" colspan="1" rowspan="1">33.95</td>
<td align="left" colspan="1" rowspan="1">32.15</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>The time to virological rebound depends on both the cost of resistance (‘selective disadvantage’, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e339" xlink:type="simple"/></inline-formula>) and the choice of drugs. Each table entry shows the time to virological rebound in [days] in an ensemble of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e340" xlink:type="simple"/></inline-formula> hybrid stochastic deterministic simulations, where we assumed that the efficacy of the drugs against the wild type was <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e341" xlink:type="simple"/></inline-formula>. The drug was <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e342" xlink:type="simple"/></inline-formula> effective against an one-mutation strain and completely inefficient against the double-mutant. The fraction of non-infectious viruses (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e343" xlink:type="simple"/></inline-formula>) was set to one-third and the initial population was assumed to be all wild type. The viral load was said to be rebounded, if the viral load reached 90% of the pre-treatment viral load.</p></fn></table-wrap-foot></table-wrap>
<p>For integrase inhibitors, the difference between the decay of plasma viral load and their predicted long-term efficacy is quite pronounced. Their comparably shorter times to virological rebound are in strong contrast to their steep initial decrease of plasma viral load (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>), but consistent with the decay pattern of the reproductive capacity (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>). For the EIs, RTIs, PIs and MIs, the predicted time to virological rebound is also much more consistent with the decay characteristics of the reproductive capacity (<xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref>) than with the decay pattern of total viral load (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>).</p>
</sec></sec><sec id="s3">
<title>Discussion</title>
<p>In clinical studies, the first approved integrase inhibitor, raltegravir, induced an extremely rapid decline in viral load when applied both as monotherapy <xref ref-type="bibr" rid="pcbi.1000720-Markowitz1">[10]</xref> and in combination with an optimized NRTI background therapy <xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-Steigbigel1">[24]</xref>. While it was initially speculated that the observed decline might be a result of superior potency of raltegravir, it is now emerging that the viral decline in InI-based therapy could be a class-specific phenomenon <xref ref-type="bibr" rid="pcbi.1000720-Dayam1">[25]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-DeJesus1">[26]</xref>. Moreover, superior potency of InIs (in terms of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e344" xlink:type="simple"/></inline-formula>) was not confirmed by single-round infectivity assays <xref ref-type="bibr" rid="pcbi.1000720-Shen1">[14]</xref>. The mechanisms underlying the decay dynamics are still not clear <xref ref-type="bibr" rid="pcbi.1000720-Goffinet1">[58]</xref> and controversially discussed <xref ref-type="bibr" rid="pcbi.1000720-Murray1">[21]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref>.</p>
<p>In <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref>, a two stage model of the viral replication cycle is presented, which explains the differences between the decay of viral load between RTIs and InIs based on the stage at which the drugs affect the dynamics of viral replication. The model explicitly distinguishes two viral stages, early-stage infected cells and late-stage infected target cells, which are specifically defined for a pair of drugs under examination. The authors further conclude that the viral dynamics produced by drugs from different anti-retroviral classes should not be directly compared to infer drug potency <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat2">[33]</xref>. An alternative measure, as it is imperative for guiding drug discovery and prioritizing drug candidates in later development stages, is still lacking.</p>
<p>All currently approved antivirals exert their effect by inhibiting the replication of HIV. The extent at which replication is inhibited, is therefore a unifying indicator for drug efficacy across all drug classes. Replication assays, e.g., phenotypic assays <xref ref-type="bibr" rid="pcbi.1000720-Petropoulos1">[15]</xref> or replication capacity assays <xref ref-type="bibr" rid="pcbi.1000720-Nicastri1">[59]</xref>, analyze drug efficacy in terms of viral replication <italic>in vitro</italic>. The replicative fitness of HIV <italic>in vivo</italic>, however, depends on the interaction of a multitude of viral and host factors. Replication assays represent the dynamics of HIV under the assay conditions, which lack many host factors, in particular the immune responses to the infection. However, since it is particularly useful to compare compounds in terms of replication inhibition, we adopt the dynamic approach of replication assays to define the reproductive capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e345" xlink:type="simple"/></inline-formula>. <italic>In silico</italic>, we are able to consider the host response to the viral infection and can thus extrapolate the replication approach from <italic>in vitro</italic> to <italic>in vivo</italic>. In <xref ref-type="bibr" rid="pcbi.1000720-Rong1">[60]</xref>, the authors used a similar approach to compare the effect of distinct antiviral classes utilizing age-structured models.</p>
<p>We derived a single detailed model of the viral replication cycle and deduced a reduced two stage model, which incorporates the action of <italic>all</italic> approved HIV drugs. Our two-stage model allows to predict the action of <italic>any number</italic> of drugs simultaneously, including common HAART cocktails, potentially belonging to different drug classes. In contrast, in <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref>, the stages of the two-stage model of viral replication are not specified <italic>a priori</italic> and have to be determined by the <italic>two</italic> drugs that are analyzed and compared.</p>
<p>Based on the proposed detailed and reduced model, we identify the following effects of currently approved drugs: EI and RTIs decrease the infection rate and thus the number of new infections. The impact on the release of new virus (and virus decline) is therefore delayed by the viral life cycle. MIs and PIs do not interfere with the total amount of virus that is being released, but rather shift the ratio of infective to total virus, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e346" xlink:type="simple"/></inline-formula> (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5</xref>, inset), which is not directly reflected by total plasma viral load. Since the kinetics of the free virus are rapid <xref ref-type="bibr" rid="pcbi.1000720-Ramratnam1">[54]</xref>, this has an immediate impact on the number of new infections. Subsequently, this impact on the number of new infections affects the total viral release (and thus total plasma virus load) in a similar manner as EIs and RTIs, creating a ‘shoulder’ phase. Hence, we obtain<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e347" xlink:type="simple"/><label>(23)</label></disp-formula>In our model, EIs, RTIs, PIs and MIs produce an identical decay of plasma viral load (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>), when assuming 100% inhibition, respectively. In particular, the onset of viral load decay is similarly delayed (‘shoulder phase’) with these inhibitors (see <xref ref-type="supplementary-material" rid="pcbi.1000720.s002">Figure S1</xref>), in agreement with clinical observations <xref ref-type="bibr" rid="pcbi.1000720-Louie1">[12]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Perelson1">[27]</xref>. Previously discussed theoretical differences in the viral response between RTIs and PIs (see Eq. (5.7) vs. Eq. (5.16) in <xref ref-type="bibr" rid="pcbi.1000720-Perelson3">[61]</xref>) yield similar dynamics when more recent (higher) estimates of viral clearance are used <xref ref-type="bibr" rid="pcbi.1000720-Ramratnam1">[54]</xref>.</p>
<p>In contrast to other inhibitor classes, InIs decrease the amount of late infected cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e348" xlink:type="simple"/></inline-formula>) (see <xref ref-type="fig" rid="pcbi-1000720-g002">Fig. 2</xref>), which has an immediate impact on total virus release, i.e.,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e349" xlink:type="simple"/><label>(24)</label></disp-formula>The impact of InIs on viral load decay is immediate and not delayed by the viral replication cycle as in the case of all other compounds <xref ref-type="bibr" rid="pcbi.1000720-Louie1">[12]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Perelson1">[27]</xref>. Thus, the onset of observed total viral decay is faster for InIs than for other compounds, irrespective of their potency (which was set equal for all compounds in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>). Furthermore, the decay of viral load in the first phase is steeper for InIs in comparison to other inhibitor classes (see <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>). The viral load decline in the first phase is proportional to the decay of the late infected T-cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e350" xlink:type="simple"/></inline-formula> (see <xref ref-type="fig" rid="pcbi-1000720-g006">Fig. 6</xref>). Sedaghat et al. <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref> derived analytical solutions for the viral decay dynamics after InI and RTI treatment (see Eqs. (9) and (10) in <xref ref-type="bibr" rid="pcbi.1000720-Sedaghat1">[32]</xref>), which demonstrate that the viral decay after InI treatment is determined by the death rate of late infected cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e351" xlink:type="simple"/></inline-formula>), while in the case of RTI treatment, the decay is determined by the “flushing-out” of the early infected cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e352" xlink:type="simple"/></inline-formula>) and the death rate of the late infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e353" xlink:type="simple"/></inline-formula>, leading to overall faster viral declines in the case of InI treatment in the first phase.</p>
<p>The long-term <italic>in vivo</italic> efficacy of an antiviral drug depends on many different factors, particularly the ability of the virus to adapt to the pharmacological challenge by developing resistance mutations. The ability to develop drug resistance is strongly dependent on the induced pattern of resistance mutations against a particular drug, but might also be influenced by the velocity at which replication competent compartments are removed from the body. However, viral load decay focusses on only one single variable, namely the total output of virus, whereas other infectious stages (e.g. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e354" xlink:type="simple"/></inline-formula>) remain ‘hidden’. Furthermore, the ratio of infective virus-to-total virus (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e355" xlink:type="simple"/></inline-formula>) is not resolved, which might underestimate the long-term efficacy of PIs and MIs that target this ratio (see <xref ref-type="table" rid="pcbi-1000720-t002">Table 2</xref> in relation to <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5A</xref>). In the section ‘The pattern of virological removal influences the time to virological rebound after treatment application’, we have compared the impact of drug-class specific removal patterns on the long-term efficacy of antivirals (in terms of resistance development). We showed that although inhibition <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e356" xlink:type="simple"/></inline-formula> was assumed to be identical across all drug classes, the times to virological rebound (used as a measure of long-term efficacy) differed, with PIs showing the longest time to virologically rebound, and InIs the shortest.</p>
<p>The reproductive capacity has been monitored over time in <xref ref-type="fig" rid="pcbi-1000720-g005">Fig. 5B</xref> to depict class-specific long-term efficacy of antivirals based on the hosts' ability to clear the targeted infectant in the viral life cycle. The main conclusion is that the long-term efficacy is larger for compounds that target viral life-stages that are cleared at a fast rate. It is generally assumed that the free virus is cleared at the fastest rate <xref ref-type="bibr" rid="pcbi.1000720-Perelson1">[27]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Ramratnam1">[54]</xref>. Since MIs and PIs reduce the production of infective virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e357" xlink:type="simple"/></inline-formula> (see <xref ref-type="fig" rid="pcbi-1000720-g002">Fig. 2</xref>), they reduce the virus' ability to produce offspring faster than all other drug classes. Furthermore, since resistance development is correlated with the extent of replication, we infer that PIs and MIs, based on their viral target, are the most efficient drug classes in terms of reducing the probability of resistance development. This assumption correlates well with the observed rebound times in <xref ref-type="table" rid="pcbi-1000720-t002">Table 2</xref> and is also supported by the fact that the introduction of PIs marked the success of HAART <xref ref-type="bibr" rid="pcbi.1000720-Hammer1">[1]</xref>.</p>
<p>During drug discovery, the pre-clinical- and the clinical development process, <italic>in vitro</italic> surrogate measures or <italic>in vivo</italic> drug efficacy measures are important to prioritize drug candidates.</p>
<p>The mechanistic mode of action of a compound at its target site can be elucidated by cell free assays that use purified viral protein, e.g. reverse transcriptase for RTIs. The influence of viral mutation, the immune system and pharmacokinetics are absent in this type of assay. However, it is possible to deduce the pharmacodynamic mode (e.g. Eq. (1), see also <xref ref-type="bibr" rid="pcbi.1000720-vonKleist1">[41]</xref>) and thus the parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e358" xlink:type="simple"/></inline-formula> from these types of assays, which denotes the extent of inhibition of the molecular process by the compound. Mathematical models of HIV dynamics use a minimal number of parameters, making them suitable for parameter fitting and comparison with clinical data. The parameters used in the models are often lumped, summarizing many viral processes. For example, binding, fusion and reverse transcription are part of the infection rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e359" xlink:type="simple"/></inline-formula> (see Eq. (3)). Inhibition of lumped model parameters (denoted by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e360" xlink:type="simple"/></inline-formula>) might therefore differ from inhibition of the molecular process <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e361" xlink:type="simple"/></inline-formula>, which is measured by cell-free <italic>in vitro</italic> assays. We have provided equations (Eqs. (S24) and (S31), Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>) that enable the use of pharmacodynamic information <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e362" xlink:type="simple"/></inline-formula>, derived from cell free assays (inhibition of the targeted molecular process), in a (lumped) mathematical model of HIV dynamics (utilizing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e363" xlink:type="simple"/></inline-formula>).</p>
<p>The presented model can be extended to incorporate drug-specific escape pathways <xref ref-type="bibr" rid="pcbi.1000720-Beerenwinkel1">[62]</xref>,<xref ref-type="bibr" rid="pcbi.1000720-Beerenwinkel2">[63]</xref> or realistic time-varying drug pharmacokinetics <xref ref-type="bibr" rid="pcbi.1000720-vonKleist1">[41]</xref>. If <italic>in vivo</italic> pharmacokinetic data is available (in terms of time-varying concentrations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e364" xlink:type="simple"/></inline-formula> in Eq. (1)), then extrapolation from <italic>in vitro</italic> to <italic>in vivo</italic> is possible and the mechanistic understanding of drug effects, its parametrization and extrapolation is facilitated. For RTIs and PIs, we found a nonlinear relationship between <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e365" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e366" xlink:type="simple"/></inline-formula> (see Eqs. (S24) and (S31), Supplementary <xref ref-type="supplementary-material" rid="pcbi.1000720.s001">Text S1</xref>). Utilization of Eqs. (S24) and (S31) allows to simulate drug effects based on their mechanistic understanding in a lumped model, that can be compared with clinical data.</p>
<p>The model can also be extended to include latently infected cells (very long lived infected cells). We did not consider them in this study, since they are expected to contribute little to the dynamics analyzed herein (the first and the second decay phase).</p>
<p>The reproductive capacity is a useful concept to analyze and monitor drug efficacy <italic>in silico</italic>. In its current form, the reproductive capacity requires detailed knowledge about (i) the composition of the viral population, and (ii) the fitness of the different viral strains under a given treatment (reproductive numbers, Eqs. (12) and (16)–(19)).</p>
<p>The fitness of certain viral strains can be assessed <italic>in vitro</italic>, e.g., by phenotypic assays. We model strain specific fitness <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e367" xlink:type="simple"/></inline-formula> under treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e368" xlink:type="simple"/></inline-formula>, in terms of two parameters: the selective disadvantage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e369" xlink:type="simple"/></inline-formula>, which denotes the loss in replication of mutant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e370" xlink:type="simple"/></inline-formula>, relative to the wild type; and the efficacy of treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e371" xlink:type="simple"/></inline-formula> against mutant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e372" xlink:type="simple"/></inline-formula> in terms of the parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e373" xlink:type="simple"/></inline-formula>. The selective disadvantage can, e.g., be estimated by performing a phenotypic assay with a certain mutant virus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e374" xlink:type="simple"/></inline-formula> in the absence of drug and then comparing it to the assay with the wild type. The parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e375" xlink:type="simple"/></inline-formula> is already being assessed in practice (e.g., <xref ref-type="bibr" rid="pcbi.1000720-Petropoulos1">[15]</xref>), usually in terms of a fold increase in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e376" xlink:type="simple"/></inline-formula>.</p>
<p>Acquisition of detailed knowledge about the composition of the viral population might, due to recent advances in sequencing technology <xref ref-type="bibr" rid="pcbi.1000720-Eriksson1">[64]</xref>–<xref ref-type="bibr" rid="pcbi.1000720-Le1">[67]</xref>, become feasible in the future. However, novel sequencing technology requires large amounts of viral RNA, which cannot be derived when the viral load is below the limits of detection.</p>
</sec><sec id="s4" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Realization of hybrid simulations</title>
<p>The overall virus dynamics in our model comprise different viral strains with copy numbers that can vary over several orders of magnitude. For this reason we have chosen a hybrid (stochastic deterministic) setting for numerical simulation. This approach (i) takes stochastic fluctuations in the slow reaction processes into account; and (ii) reduces the computational costs for the simulation of the fast (deterministic) system dynamics. We used the direct hybrid method proposed in <xref ref-type="bibr" rid="pcbi.1000720-Alfonsi1">[51]</xref>. Elementary reactions were treated stochastically whenever their propensity function or the quantity of at least one of their reactants was below a certain threshold (for all numerical simulations this threshold was set to 5). For the numerical integration of the deterministic part of the system, we implemented a solver in C++ that is based on numerical differentiation formulas <xref ref-type="bibr" rid="pcbi.1000720-Klopfenstein1">[68]</xref> and uses strategies for error control and step size control comparable to ode15s in Matlab <xref ref-type="bibr" rid="pcbi.1000720-Shampine1">[69]</xref>. To generate the data for <xref ref-type="table" rid="pcbi-1000720-t002">Table 2</xref>, we performed 1000 hybrid simulations for each condition. With realization start (<italic>t</italic> = 0), the effects of the drug treatment were simulated until the viral population size reached 90% of its pre-treatment value, i.e., virological rebound occurred. During a simulation, the stochastic partitioning of the reaction system was dynamically updated and stochastic reaction events were realized accordingly. Every numerical calculation was computed with a relative error tolerance of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e377" xlink:type="simple"/></inline-formula> and an absolute error tolerance of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000720.e378" xlink:type="simple"/></inline-formula>. The hybrid simulations for <xref ref-type="table" rid="pcbi-1000720-t002">Table 2</xref> were performed on two Intel Quad-Core Xeon E5345 processors with 2.33 GHz and 32 GB RAM, which took nearly 46 hours in total or approximately 6 seconds per simulation, respectively.</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1000720.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.s001" xlink:type="simple"><label>Text S1</label><caption>
<p>This file contains the derivation of the simplified model (<xref ref-type="fig" rid="pcbi-1000720-g003">Fig. 3</xref>) from the detailed model (<xref ref-type="fig" rid="pcbi-1000720-g001">Fig. 1</xref>).</p>
<p>(0.30 MB PDF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1000720.s002" mimetype="application/postscript" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000720.s002" xlink:type="simple"><label>Figure S1</label><caption>
<p>Delay in the onset of viral load decay, exemplified for PI treatment. Simulation results (red line) using the novel two stage virus dynamics model and simulating 100% effective PI treatment are shown together with median clinical data (black diamonds) from PI (RTV) monotherapy.</p>
<p>(0.91 MB EPS)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>Insightful discussions with Prof. Rick Middleton (NUIM) are kindly acknowledged. We are very grateful to the National University of Ireland in Maynooth and the Free University of Berlin for providing computing time on their high-performance clusters. Special thanks to Vanush Misha Paturyan for assistance in scheduling jobs on the computing cluster at NUIM.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1000720-Hammer1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hammer</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Squires</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Hughes</surname><given-names>MD</given-names></name>
<name name-style="western"><surname>Grimes</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Demeter</surname><given-names>LM</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team.</article-title>             <source>N Engl J Med</source>             <volume>337</volume>             <fpage>725</fpage>             <lpage>733</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Hirsch1"><label>2</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hirsch</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Steigbigel</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Staszewski</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Mellors</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Scerpella</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.</article-title>             <source>J Infect Dis</source>             <volume>180</volume>             <fpage>659</fpage>             <lpage>665</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Richman1"><label>3</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Richman</surname><given-names>DD</given-names></name>
</person-group>             <year>2001</year>             <article-title>HIV chemotherapy.</article-title>             <source>Nature</source>             <volume>410</volume>             <fpage>995</fpage>             <lpage>1001</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Kulkosky1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kulkosky</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Pomerantz</surname><given-names>RJ</given-names></name>
</person-group>             <year>2002</year>             <article-title>Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.</article-title>             <source>Clin Infect Dis</source>             <volume>35</volume>             <fpage>1520</fpage>             <lpage>1526</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Kulkosky2"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kulkosky</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Nunnari</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Otero</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Calarota</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Dornadula</surname><given-names>G</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.</article-title>             <source>J Infect Dis</source>             <volume>186</volume>             <fpage>1403</fpage>             <lpage>1411</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Finzi1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hermankova</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pierson</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Carruth</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Buck</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.</article-title>             <source>Science</source>             <volume>278</volume>             <fpage>1295</fpage>             <lpage>1300</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Wong1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wong</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Hezareh</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Günthard</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Ignacio</surname><given-names>CC</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.</article-title>             <source>Science</source>             <volume>278</volume>             <fpage>1291</fpage>             <lpage>1295</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Current1"><label>8</label><element-citation publication-type="other" xlink:type="simple">             <comment>Current HIV treatment guidelines: (<ext-link ext-link-type="uri" xlink:href="http://www.aidsinfo.nih.gov/guidelines/" xlink:type="simple">http://www.aidsinfo.nih.gov/guidelines/</ext-link>). Technical report, National Institute of Health (accessed 15-Feb-2010)</comment>          </element-citation></ref>
<ref id="pcbi.1000720-Langford1"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Langford</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Ananworanich</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name>
</person-group>             <year>2007</year>             <article-title>Predictors of disease progression in HIV infection: a review.</article-title>             <source>AIDS Res Ther</source>             <volume>4</volume>             <fpage>11</fpage>          </element-citation></ref>
<ref id="pcbi.1000720-Markowitz1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Morales-Ramirez</surname><given-names>JO</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>BY</given-names></name>
<name name-style="western"><surname>Kovacs</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Steigbigel</surname><given-names>RT</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>Antiretroviral activity, pharmacokinetics, and tolerability of mk-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>43</volume>             <fpage>509</fpage>             <lpage>515</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Ftkenheuer1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Fätkenheuer</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Pozniak</surname><given-names>AL</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Plettenberg</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Staszewski</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.</article-title>             <source>Nat Med</source>             <volume>11</volume>             <fpage>1170</fpage>             <lpage>1172</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Louie1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Louie</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hogan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Mascio</surname><given-names>MD</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Simon</surname><given-names>V</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Determining the relative efficacy of highly active antiretroviral therapy.</article-title>             <source>J Infect Dis</source>             <volume>187</volume>             <fpage>896</fpage>             <lpage>900</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Zhang1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Alcock</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Kiefer</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Monie</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.</article-title>             <source>J Virol</source>             <volume>78</volume>             <fpage>1718</fpage>             <lpage>1729</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Shen1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Peterson</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>McMahon</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Callender</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.</article-title>             <source>Nat Med</source>             <volume>14</volume>             <fpage>762</fpage>             <lpage>766</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Petropoulos1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Petropoulos</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Parkin</surname><given-names>NT</given-names></name>
<name name-style="western"><surname>Limoli</surname><given-names>KL</given-names></name>
<name name-style="western"><surname>Lie</surname><given-names>YS</given-names></name>
<name name-style="western"><surname>Wrin</surname><given-names>T</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>44</volume>             <fpage>920</fpage>             <lpage>928</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Hachiya1"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hachiya</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Aizawa-Matsuoka</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Ida</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1–10 (magic-5).</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>45</volume>             <fpage>495</fpage>             <lpage>501</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Dando1"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dando</surname><given-names>TM</given-names></name>
<name name-style="western"><surname>Perry</surname><given-names>CM</given-names></name>
</person-group>             <year>2003</year>             <article-title>Enfuvirtide.</article-title>             <source>Drugs</source>             <volume>63</volume>             <fpage>2755</fpage>             <lpage>66</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Carter1"><label>18</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Carter</surname><given-names>NJ</given-names></name>
<name name-style="western"><surname>Keating</surname><given-names>GM</given-names></name>
</person-group>             <year>2007</year>             <article-title>Maraviroc.</article-title>             <source>Drugs</source>             <volume>67</volume>             <fpage>2277</fpage>             <lpage>88</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Croxtall1"><label>19</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Croxtall</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Lyseng-Williamson</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Perry</surname><given-names>CM</given-names></name>
</person-group>             <year>2008</year>             <article-title>Raltegravir.</article-title>             <source>Drugs</source>             <volume>68</volume>             <fpage>131</fpage>             <lpage>138</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Investigational1"><label>20</label><element-citation publication-type="other" xlink:type="simple">             <comment>Investigational drugs: (<ext-link ext-link-type="uri" xlink:href="http://www.aidsinfo.nih.gov/" xlink:type="simple">http://www.aidsinfo.nih.gov/</ext-link>). Technical report, National Institute of Health (accessed 15-Feb-2010)</comment>          </element-citation></ref>
<ref id="pcbi.1000720-Murray1"><label>21</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Murray</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Emery</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name>
<name name-style="western"><surname>Law</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.</article-title>             <source>AIDS</source>             <volume>21</volume>             <fpage>2315</fpage>             <lpage>2321</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Grinsztejn1"><label>22</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>BY</given-names></name>
<name name-style="western"><surname>Katlama</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Gatell</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Lazzarin</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (mk-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.</article-title>             <source>Lancet</source>             <volume>369</volume>             <fpage>1261</fpage>             <lpage>1269</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Markowitz2"><label>23</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>BY</given-names></name>
<name name-style="western"><surname>Gotuzzo</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Mendo</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Ratanasuwan</surname><given-names>W</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>46</volume>             <fpage>125</fpage>             <lpage>133</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Steigbigel1"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Steigbigel</surname><given-names>RT</given-names></name>
<name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>PN</given-names></name>
<name name-style="western"><surname>Eron</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Schechter</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Raltegravir with optimized background therapy for resistant HIV-1 infection.</article-title>             <source>N Engl J Med</source>             <volume>359</volume>             <fpage>339</fpage>             <lpage>354</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Dayam1"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dayam</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Al-Mawsawi</surname><given-names>LQ</given-names></name>
<name name-style="western"><surname>Neamati</surname><given-names>N</given-names></name>
</person-group>             <year>2007</year>             <article-title>HIV-1 integrase inhibitors: an emerging clinical reality.</article-title>             <source>Drugs R D</source>             <volume>8</volume>             <fpage>155</fpage>             <lpage>168</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-DeJesus1"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>DeJesus</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Berger</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Cohen</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Hawkins</surname><given-names>T</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor gs-9137 (jtk-303) in treatment-naive and treatment-experienced patients.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>43</volume>             <fpage>1</fpage>             <lpage>5</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Perelson1"><label>27</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>
</person-group>             <year>1996</year>             <article-title>HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.</article-title>             <source>Science</source>             <volume>271</volume>             <fpage>1582</fpage>             <lpage>1586</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Perelson2"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Essunger</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Vesanen</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Decay characteristics of HIV-1-infected compartments during combination therapy.</article-title>             <source>Nature</source>             <volume>387</volume>             <fpage>188</fpage>             <lpage>191</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Ho1"><label>29</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>
<name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name>
<etal/></person-group>             <year>1995</year>             <article-title>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.</article-title>             <source>Nature</source>             <volume>373</volume>             <fpage>123</fpage>             <lpage>126</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Bonhoeffer1"><label>30</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>May</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Shaw</surname><given-names>GM</given-names></name>
<name name-style="western"><surname>Nowak</surname><given-names>MA</given-names></name>
</person-group>             <year>1997</year>             <article-title>Virus dynamics and drug therapy.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>94</volume>             <fpage>6971</fpage>             <lpage>6976</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Nowak1"><label>31</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Nowak</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Bangham</surname><given-names>CR</given-names></name>
</person-group>             <year>1996</year>             <article-title>Population dynamics of immune responses to persistent viruses.</article-title>             <source>Science</source>             <volume>272</volume>             <fpage>74</fpage>             <lpage>79</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Sedaghat1"><label>32</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Dinoso</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Wilke</surname><given-names>CO</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2008</year>             <article-title>Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>4832</fpage>             <lpage>4837</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Sedaghat2"><label>33</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
<name name-style="western"><surname>Wilke</surname><given-names>CO</given-names></name>
</person-group>             <year>2009</year>             <article-title>Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.</article-title>             <source>Antivir Ther</source>             <volume>14</volume>             <fpage>263</fpage>             <lpage>271</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Pettit1"><label>34</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pettit</surname><given-names>SC</given-names></name>
<name name-style="western"><surname>Lindquist</surname><given-names>JN</given-names></name>
<name name-style="western"><surname>Kaplan</surname><given-names>AH</given-names></name>
<name name-style="western"><surname>Swanstrom</surname><given-names>R</given-names></name>
</person-group>             <year>2005</year>             <article-title>Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.</article-title>             <source>Retrovirology</source>             <volume>2</volume>             <fpage>66</fpage>          </element-citation></ref>
<ref id="pcbi.1000720-Wiegers1"><label>35</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wiegers</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Rutter</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Kottler</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Tessmer</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Hohenberg</surname><given-names>H</given-names></name>
<etal/></person-group>             <year>1998</year>             <article-title>Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.</article-title>             <source>J Virol</source>             <volume>72</volume>             <fpage>2846</fpage>             <lpage>2854</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Ross1"><label>36</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ross</surname><given-names>J</given-names></name>
</person-group>             <year>1995</year>             <article-title>mRNA stability in mammalian cells.</article-title>             <source>Microbiol Rev</source>             <volume>59</volume>             <fpage>423</fpage>             <lpage>450</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Houseley1"><label>37</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Houseley</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Tollervey</surname><given-names>D</given-names></name>
</person-group>             <year>2009</year>             <article-title>The many pathways of RNA degradation.</article-title>             <source>Cell</source>             <volume>136</volume>             <fpage>763</fpage>             <lpage>776</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Mangeat1"><label>38</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mangeat</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Turelli</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Caron</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Friedli</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Perrin</surname><given-names>L</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.</article-title>             <source>Nature</source>             <volume>424</volume>             <fpage>99</fpage>             <lpage>103</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Rosario1"><label>39</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rosario</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Poland</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Sullivan</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Westby</surname><given-names>M</given-names></name>
<name name-style="western"><surname>van der Ryst</surname><given-names>E</given-names></name>
</person-group>             <year>2006</year>             <article-title>A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>42</volume>             <fpage>183</fpage>             <lpage>191</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Jacqmin1"><label>40</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jacqmin</surname><given-names>P</given-names></name>
<name name-style="western"><surname>McFadyen</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Wade</surname><given-names>JR</given-names></name>
</person-group>             <year>2008</year>             <article-title>A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.</article-title>             <source>Br J Clin Pharmacol</source>             <volume>65</volume>             <supplement>Suppl 1</supplement>             <fpage>95</fpage>             <lpage>106</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-vonKleist1"><label>41</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>von Kleist</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Huisinga</surname><given-names>W</given-names></name>
</person-group>             <year>2009</year>             <article-title>Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine.</article-title>             <source>Eur J Pharm Sci</source>             <volume>36</volume>             <fpage>532</fpage>             <lpage>543</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Hazuda1"><label>42</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hazuda</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Felock</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Witmer</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Wolfe</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Stillmock</surname><given-names>K</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.</article-title>             <source>Science</source>             <volume>287</volume>             <fpage>646</fpage>             <lpage>650</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Neamati1"><label>43</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Neamati</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Hong</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Owen</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Sunder</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Winslow</surname><given-names>HE</given-names></name>
<etal/></person-group>             <year>1998</year>             <article-title>Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.</article-title>             <source>J Med Chem</source>             <volume>41</volume>             <fpage>3202</fpage>             <lpage>3209</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Grobler1"><label>44</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Grobler</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Stillmock</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Witmer</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Felock</surname><given-names>P</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>99</volume>             <fpage>6661</fpage>             <lpage>6666</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Marchand1"><label>45</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Marchand</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Karki</surname><given-names>RG</given-names></name>
<name name-style="western"><surname>Pais</surname><given-names>GCG</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (f185k/c280s).</article-title>             <source>Mol Pharmacol</source>             <volume>64</volume>             <fpage>600</fpage>             <lpage>609</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Salzwedel1"><label>46</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Salzwedel</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Martin</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Sakalian</surname><given-names>M</given-names></name>
</person-group>             <year>2007</year>             <article-title>Maturation inhibitors: a new therapeutic class targets the virus structure.</article-title>             <source>AIDS Rev</source>             <volume>9</volume>             <fpage>162</fpage>             <lpage>172</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Krusslich1"><label>47</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kräusslich</surname><given-names>HG</given-names></name>
<name name-style="western"><surname>Fäcke</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Heuser</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Konvalinka</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zentgraf</surname><given-names>H</given-names></name>
</person-group>             <year>1995</year>             <article-title>The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity.</article-title>             <source>J Virol</source>             <volume>69</volume>             <fpage>3407</fpage>             <lpage>3419</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Pettit2"><label>48</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pettit</surname><given-names>SC</given-names></name>
<name name-style="western"><surname>Moody</surname><given-names>MD</given-names></name>
<name name-style="western"><surname>Wehbie</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Kaplan</surname><given-names>AH</given-names></name>
<name name-style="western"><surname>Nantermet</surname><given-names>PV</given-names></name>
<etal/></person-group>             <year>1994</year>             <article-title>The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.</article-title>             <source>J Virol</source>             <volume>68</volume>             <fpage>8017</fpage>             <lpage>8027</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Li1"><label>49</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Goila-Gaur</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Salzwedel</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Kilgore</surname><given-names>NR</given-names></name>
<name name-style="western"><surname>Reddick</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in gag processing.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>100</volume>             <fpage>13555</fpage>             <lpage>13560</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Mansky1"><label>50</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mansky</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Temin</surname><given-names>HM</given-names></name>
</person-group>             <year>1995</year>             <article-title>Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.</article-title>             <source>J Virol</source>             <volume>69</volume>             <fpage>5087</fpage>             <lpage>5094</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Alfonsi1"><label>51</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Alfonsi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Cancès</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Turinici</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Ventura</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Huisinga</surname><given-names>W</given-names></name>
</person-group>             <year>2005</year>             <article-title>Exact simulation of hybrid stochastic and deterministic models for biochemical systems.</article-title>             <source>ESAIM Proc</source>             <volume>14</volume>             <fpage>1</fpage>             <lpage>23</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Heesterbeek1"><label>52</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Heesterbeek</surname><given-names>JAP</given-names></name>
</person-group>             <year>2002</year>             <article-title>A brief history of R0 and a recipe for its calculation.</article-title>             <source>Acta Biotheor</source>             <volume>50</volume>             <fpage>189</fpage>             <lpage>204</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Heffernan1"><label>53</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Heffernan</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Wahl</surname><given-names>LM</given-names></name>
</person-group>             <year>2005</year>             <article-title>Perspectives on the basic reproductive ratio.</article-title>             <source>J R Soc Interface</source>             <volume>2</volume>             <fpage>281</fpage>             <lpage>293</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Ramratnam1"><label>54</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ramratnam</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Binley</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.</article-title>             <source>Lancet</source>             <volume>354</volume>             <fpage>1782</fpage>             <lpage>1785</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Nijhuis1"><label>55</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Nijhuis</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Schuurman</surname><given-names>R</given-names></name>
<name name-style="western"><surname>de Jong</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Erickson</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Gustchina</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.</article-title>             <source>AIDS</source>             <volume>13</volume>             <fpage>2349</fpage>             <lpage>2359</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Havlir1"><label>56</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Eastman</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gamst</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Richman</surname><given-names>DD</given-names></name>
</person-group>             <year>1996</year>             <article-title>Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.</article-title>             <source>J Virol</source>             <volume>70</volume>             <fpage>7894</fpage>             <lpage>7899</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Wei1"><label>57</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wei</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Ghosh</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Taylor</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>VA</given-names></name>
<name name-style="western"><surname>Emini</surname><given-names>EA</given-names></name>
<etal/></person-group>             <year>1995</year>             <article-title>Viral dynamics in human immunodeficiency virus type 1 infection.</article-title>             <source>Nature</source>             <volume>373</volume>             <fpage>117</fpage>             <lpage>122</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Goffinet1"><label>58</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Goffinet</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Allespach</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Oberbremer</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Golden</surname><given-names>PL</given-names></name>
<name name-style="western"><surname>Foster</surname><given-names>SA</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.</article-title>             <source>J Virol</source>             <volume>83</volume>             <fpage>7706</fpage>             <lpage>7717</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Nicastri1"><label>59</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Nicastri</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Sarmati</surname><given-names>L</given-names></name>
<name name-style="western"><surname>d'Ettorre</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Palmisano</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Parisi</surname><given-names>SG</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Replication capacity, biological phenotype, and drug resistance of hiv strains isolated from patients failing antiretroviral therapy.</article-title>             <source>J Med Virol</source>             <volume>69</volume>             <fpage>1</fpage>             <lpage>6</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Rong1"><label>60</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2007</year>             <article-title>Mathematical analysis of age-structured hiv-1 dynamics with combination antiretroviral therapy.</article-title>             <source>Siam J Appl Math</source>             <volume>67</volume>             <fpage>731</fpage>             <lpage>756</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Perelson3"><label>61</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Nelson</surname><given-names>PW</given-names></name>
</person-group>             <year>1999</year>             <article-title>Mathematical analysis of HIV-1 dynamics in vivo.</article-title>             <source>SIAM Review</source>             <volume>41</volume>             <fpage>3</fpage>             <lpage>44</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Beerenwinkel1"><label>62</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Beerenwinkel</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Rahnenführer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Däumer</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hoffmann</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Kaiser</surname><given-names>R</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Learning multiple evolutionary pathways from cross-sectional data.</article-title>             <source>J Comput Biol</source>             <volume>12</volume>             <fpage>584</fpage>             <lpage>598</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Beerenwinkel2"><label>63</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Beerenwinkel</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Däumer</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Sing</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Rahnenfuhrer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Lengauer</surname><given-names>T</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.</article-title>             <source>J Infect Dis</source>             <volume>191</volume>             <fpage>1953</fpage>             <lpage>1960</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Eriksson1"><label>64</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Eriksson</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Pachter</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Mitsuya</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Rhee</surname><given-names>SY</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Viral population estimation using pyrosequencing.</article-title>             <source>PLoS Comput Biol</source>             <volume>4</volume>             <fpage>e1000074</fpage>          </element-citation></ref>
<ref id="pcbi.1000720-Bushman1"><label>65</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bushman</surname><given-names>FD</given-names></name>
<name name-style="western"><surname>Hoffmann</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Ronen</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Malani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Minkah</surname><given-names>N</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Massively parallel pyrosequencing in HIV research.</article-title>             <source>AIDS</source>             <volume>22</volume>             <fpage>1411</fpage>             <lpage>1415</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Rozera1"><label>66</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rozera</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Abbate</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Bruselles</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Vlassi</surname><given-names>C</given-names></name>
<name name-style="western"><surname>D'Offizi</surname><given-names>G</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Massively parallel pyrosequencing highlights minority variants in the HIV-1 Env quasispecies deriving from lymphomonocyte sub-populations.</article-title>             <source>Retrovirology</source>             <volume>6</volume>             <fpage>15</fpage>          </element-citation></ref>
<ref id="pcbi.1000720-Le1"><label>67</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Le</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Chiarella</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Simen</surname><given-names>BB</given-names></name>
<name name-style="western"><surname>Hanczaruk</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Egholm</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.</article-title>             <source>PLoS One</source>             <volume>4</volume>             <fpage>e6079</fpage>          </element-citation></ref>
<ref id="pcbi.1000720-Klopfenstein1"><label>68</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Klopfenstein</surname><given-names>R</given-names></name>
</person-group>             <year>1971</year>             <article-title>Numerical differentiation formulas for stiff systems of ordinary differential equations.</article-title>             <source>RCA Review</source>             <volume>32</volume>             <fpage>447</fpage>             <lpage>462</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Shampine1"><label>69</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Shampine</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Reichelt</surname><given-names>M</given-names></name>
</person-group>             <year>1997</year>             <article-title>The matlab ode suite.</article-title>             <source>SIAM Journal on Scientific Computing</source>             <volume>18</volume>             <fpage>1</fpage>             <lpage>22</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Rong2"><label>70</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2009</year>             <article-title>Modeling HIV persistence, the latent reservoir, and viral blips.</article-title>             <source>J Theor Biol</source>             <volume>260</volume>             <fpage>308</fpage>             <lpage>331</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Kawai1"><label>71</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kawai</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Mathew</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Tanaka</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Rowland</surname><given-names>M</given-names></name>
</person-group>             <year>1998</year>             <article-title>Physiologically based pharmacokinetics of cyclosporine a: extension to tissue distribution kinetics in rats and scale-up to human.</article-title>             <source>J Pharmacol Exp Ther</source>             <volume>287</volume>             <fpage>457</fpage>             <lpage>468</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-vonKleist2"><label>72</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>von Kleist</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Huisinga</surname><given-names>W</given-names></name>
</person-group>             <year>2007</year>             <article-title>Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.</article-title>             <source>J Pharmacokinet Pharmacodyn</source>             <volume>34</volume>             <fpage>789</fpage>             <lpage>806</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Markowitz3"><label>73</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Louie</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Mascio</surname><given-names>MD</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.</article-title>             <source>J Virol</source>             <volume>77</volume>             <fpage>5037</fpage>             <lpage>5038</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Pierson1"><label>74</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pierson</surname><given-names>TC</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Kieffer</surname><given-names>TL</given-names></name>
<name name-style="western"><surname>Ruff</surname><given-names>CT</given-names></name>
<name name-style="western"><surname>Buck</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.</article-title>             <source>J Virol</source>             <volume>76</volume>             <fpage>8518</fpage>             <lpage>8531</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Zhou1"><label>75</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2005</year>             <article-title>Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.</article-title>             <source>J Virol</source>             <volume>79</volume>             <fpage>2199</fpage>             <lpage>2210</lpage>          </element-citation></ref>
<ref id="pcbi.1000720-Koelsch1"><label>76</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Koelsch</surname><given-names>KK</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Haubrich</surname><given-names>R</given-names></name>
<name name-style="western"><surname>May</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.</article-title>             <source>J Infect Dis</source>             <volume>197</volume>             <fpage>411</fpage>             <lpage>419</lpage>          </element-citation></ref>
</ref-list>

</back>
</article>